Recently, the Food and Drug Administration has approved the use of Romosozumab, a sclerostin monoclonal antibody, for the treatment of osteoporosis among postmenopausal women at high risk of fractures.107,108 The application of sclerostin antibody in DO should be further assessed. The gene discussed is SOST; the disease is osteoporosis.